<DOC>
	<DOCNO>NCT01263925</DOCNO>
	<brief_summary>Investigate , outpatient condition , effect 4 week daily treatment Prostaglandin E1 4 week interval treatment ( two infusion per week ) pain-free walk distance patient Intermittent Claudication .</brief_summary>
	<brief_title>Prostaglandin E1 Outpatients With Intermittent Claudication</brief_title>
	<detailed_description />
	<mesh_term>Intermittent Claudication</mesh_term>
	<mesh_term>Arterial Occlusive Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Pentoxifylline</mesh_term>
	<mesh_term>Alprostadil</mesh_term>
	<criteria>Subjects Peripheral Arterial Occlusive Disease ( PAOD ) low extremity Fontaine stage II Maximum walk distance treadmill ( 12 % , 3 km/h ) 30 150 Stable Intermittent Claudication least 6 month stand acute shorten walk distance past 3 month Stenoses occlusion Femoral Bifurcation ( aboveknee belowknee type ) confirm duplex US angiography Ankle/brachial index ≤ 0.90 decrease systolic ankle pressure ≥ 10 % maximum loading ( maximum walk distance treadmill 3 km/h , 12 % ) The patient physically mentally capable participate trial Patient age &gt; 40 year , male female Patient inform give ample time opportunity think her/his participation give her/his write informed consent Patient willing able comply trial requirement Surgical interventional measure perform affected extremity Prostaglandin treatment within 6 month immediately prior trial Rest pain Necroses Systolic ankle pressure le 50 mmHg Change maximum walk distance oneweek Runin Phase ± 25 % Baseline Successful physical walking training within 6 month immediately prior trial Inflammatory vascular disease Polyneuropathy Diabetes Mellitus Diseases limit walk distance ( Arthrosis , inflammatory disease joint , neurological disease , diseases Vertebral Column , cardiopulmonary disease ) History Pulmonary Oedema Myocardial infarction within past 6 month Pregnancy nurse Known hypersensitivity component trial medication comparative drug Renal insufficiency , compensate retention ( creatinine &gt; 2.0 mg/dL ) Severe retinal Haemorrhage Massive Haemorrhage Known exist malignant disease Vasoactive concomitant medication ( e.g . Naftidrofuryl , Pentoxifylline , Buflomedil , Cilostazol ) , Prostaglandins Untreated uncontrolled Hypertension ( systolic blood pressure ≥ 180 mmHg , diastolic blood pressure ≥ 110 mmHg ) Previous participation patient present trial Participation patient trial objective within past 6 month , currently participate another trial Illness patient due alcohol drugabuse within past 6 month Serious illness patient investigator considers compromise his/her participation trial</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Alprostadil</keyword>
	<keyword>Prostaglandin E1</keyword>
	<keyword>Prostavasin®</keyword>
	<keyword>PAOD</keyword>
</DOC>